Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Hematology. American Society of Hematology. Education Program|December 9, 2022
Antibodies and bispecifics for multiple myeloma: effective effector therapyChristopher Cipkar, Christine Chen, Suzanne Trudel
Future Oncology (London, England)|September 3, 2020
Belantamab mafodotin in the treatment of relapsed or refractory multiple myelomaSemira Sheikh, Eyal Lebel, Suzanne Trudel
International Journal of Hematology|May 11, 2012
Light chain deposition disease affecting the gastrointestinal tract in the setting of post-living donor kidney transplantationVictor H Jimenez-Zepeda, Rajkumar Vajpeyi, Rohan John, et al.
Blood|October 24, 2002
Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistanceJonathan B Pollett, Suzanne Trudel, Daniel Stern, et al.
Leukemia & Lymphoma|August 14, 2012
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myelomaVictor H Jimenez-Zepeda, Donna E Reece, Suzanne Trudel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 20, 2009
Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplantParneet K Cheema, Sahar Zadeh, Vishal Kukreti, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 31, 2012
Rapidity and quality of response to steroid-based induction therapy, without the addition of novel agents, does not affect post transplant outcomes in multiple myelomaAnca Prica, Young Trieu, Wei Xu, et al.
Blood|March 12, 2005
Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myelomaHong Chang, A Keith Stewart, Xiao Ying Qi, et al.
Blood|January 13, 2004
Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myelomaSuzanne Trudel, Scott Ely, Yildiz Farooqi, et al.
American Journal of Hematology|August 5, 2011
Cyclophosphamide and prednisone induction followed by cyclophosphamide mobilization effectively decreases the incidence of engraftment syndrome in patients with POEMS syndrome who undergo stem cell transplantationVictor H Jimenez-Zepeda, Suzanne Trudel, Donna E Reece, et al.
Pageof 11